杜密克治疗肝硬化引起的肝性脑病的疗效观察  

Clinical effects of Duphalac on hepatic encephalopathy in patients with liver cirrhosis

作　　者：刘天保[1] 

机构地区：[1]河南济源市中医院消化内科,济源454650

出　　处：《中国实用神经疾病杂志》2007年第1期68-69,共2页Chinese Journal of Practical Nervous Diseases

摘　　要：目的观察杜密克治疗肝硬化引起的肝性脑病的临床疗效。方法将56例由乙肝或丙肝致肝硬化而出现肝性脑病患者随机分为治疗组(n=32)和对照组(n=24)。治疗组接受杜密克口服液,对照组接受常规护肝治疗,经治疗2周后,观察临床疗效、肝功能、血氨、脑电图等变化。结果杜密克组显效9例(28.1%),有效14例(43.8%),无效9例(28.1%),死亡2例(6.3%),总有效率为71.9%;而对照组显效2例(8.3%),有效3例(12.5%),无效19例(79.2%),死亡5例(20.8%),总有效率为20.8%。两组总有效率比较差异有显著性(P<0.001)。杜密克组血氨浓度显著降低(P<0.01)。结论杜密克是预防和治疗肝炎肝硬化患者肝性脑病的有效药物,可改善临床症状。Objective To study the effects of Duphalac on hepatic encephalopathy in patients with liver cirrhosis. Methods 56 patients with hepatic encephalopathy after hepatitis B or C liver cirrhosis were randomly divided into treatment and control groups. Patients in treatment group （n=32） were treated with Duphalac, while control patients （n= 24） were treated with routine medicine. The efficacy was determined 2 wks after treatment. The serum ammonia and liver function tests were analyzed subsequently. Results In Duphalac-treated group, 9 patients （28.1%） showed marked improvement of clinical syndromes, 14 cases （43.8%） with improvement, 9 cases （28.1%） without any response, and 2 died （6.3%）, the total rate of effects was 71.9%. However, control group had 2 patients （8.3%） with marked improvement, 3 patients （12.5%） with improvement, 19 patients （79. 2%） with no response, and 5 died （20.8%）, the total rate of effects was 20. 8%. There was significantly difference in total rate of effect between 2 groups （P 〈 0.01）. The serum ammonia in Duphalactreated group was also significantly decreased than that in controls （P〈0. 05）. Conclusion Duphalac is effective in the control of hepatic encephalopathy in patients with liver cirrhosis, and improves clinical syndromes.

关 键 词：肝硬化 肝性脑病 杜密克 

分 类 号：R747.9[医药卫生—神经病学与精神病学]